Brege Laura 4
4 · Mirum Pharmaceuticals, Inc. · Filed Sep 12, 2025
Insider Transaction Report
Form 4
Brege Laura
Director
Transactions
- Exercise/Conversion
Common Stock
2025-09-11$15.00/sh+17,000$255,000→ 32,703 total - Sale
Common Stock
2025-09-11$74.34/sh−15,509$1,152,939→ 17,194 total - Sale
Common Stock
2025-09-11$75.07/sh−1,491$111,929→ 15,703 total - Exercise/Conversion
Stock Option (right to buy)
2025-09-11−17,000→ 0 totalExercise: $15.00Exp: 2029-07-16→ Common Stock (17,000 underlying)
Footnotes (3)
- [F1]The weighted average sale price for the transaction reported was $74.34, and the range of prices were between $73.73 and $74.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F2]The weighted average sale price for the transaction reported was $75.07, and the range of prices were between $74.745 and $75.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The stock option is fully vested.